Acne affects approximately 50 million people in the United States alone, making it the most common skin condition by a significant margin. Yet despite this staggering prevalence, acne remains undertreated. A young woman struggling with persistent breakouts might have been dealing with acne for years without ever seeing a dermatologist, instead cycling through drugstore treatments that provide minimal relief. This paradox—a condition affecting the majority of teenagers and millions of adults worldwide, yet remaining inadequately managed—stems from interconnected barriers that prevent people from accessing proper care. This article examines why acne’s commonality masks a crisis of undertreatment, exploring the financial obstacles, systemic gaps in healthcare access, and psychological factors that leave millions suffering with a treatable condition.
The statistics paint a stark picture. Approximately 9.4% of the global population suffers from acne, ranking it as the 8th most prevalent disease worldwide. Among young people, the numbers are even more dramatic: 85% of people aged 12 to 24 experience at least minor acne. Yet fewer than half of those affected seek professional dermatological care. Instead, they rely on trial-and-error approaches with over-the-counter products, many of which are ineffective for moderate to severe acne. Understanding why such a prevalent condition goes undertreated is essential for anyone affected by acne and for healthcare providers working to improve treatment outcomes.
Table of Contents
- What Financial Barriers Prevent Acne Treatment?
- Does Acne Lack Visibility in Healthcare Settings?
- How Do Access Disparities Affect Treatment Outcomes?
- Is Acne Becoming More Common Among Adults?
- Why Does Insurance Denial of Newer Treatments Perpetuate Undertreatment?
- How Do Regional Variations Affect Global Acne Treatment?
- What Does the Future Hold for Acne Treatment Access?
- Conclusion
What Financial Barriers Prevent Acne Treatment?
Cost and insurance coverage represent the single largest obstacle to acne treatment. research shows that 65% of patients reported cost or insufficient insurance coverage as the primary reason for not filling acne prescriptions. When people face the choice between affording prescription retinoids—which can cost $100 to $300 per month without insurance—or purchasing cheaper over-the-counter alternatives, the financial decision often overrides clinical need. This explains why 84% of acne sufferers used over-the-counter products in the past year, spending an average of $121.99 to $200 annually out of pocket.
Insurance plans frequently deny coverage for newer, more effective acne treatments like newer retinoids or hormonal therapies, defaulting instead to older generic alternatives. A patient might be prescribed tretinoin (a generic retinoid) covered by insurance while their dermatologist recommends a newer-generation treatment that isn’t covered. The patient then faces a dilemma: use an older medication that may be less effective, pay thousands out of pocket for a better option, or abandon professional treatment altogether. This system-level problem directly contributes to the undertreatment of acne, particularly among lower-income patients.
Does Acne Lack Visibility in Healthcare Settings?
Acne suffers from poor self-recognition among patients, which drives significant undertreatment. Many people experiencing acne don’t fully recognize the severity of their condition or mistakenly believe it will resolve on its own. This psychological gap between the actual condition and patient perception means that even when patients visit healthcare providers for other reasons, they often don’t mention their acne unless it’s the primary purpose of the visit. dermatologists rarely treat acne as an incidental finding requiring attention; instead, patients must actively bring it to their doctor’s attention. This creates a vicious cycle.
A patient experiencing moderate acne might visit their primary care physician for an unrelated issue—a respiratory infection, a routine checkup—and never mention their skin. The doctor, focused on the presenting problem, doesn’t screen for or inquire about acne. The patient leaves without a treatment plan, reinforcing the belief that acne isn’t worth professional attention. Meanwhile, the untreated acne continues to worsen, potentially leaving permanent scarring. Healthcare systems that emphasize problem-focused visits rather than comprehensive skin health assessment miss countless opportunities for early, effective acne intervention.
How Do Access Disparities Affect Treatment Outcomes?
Acne treatment access is not equally distributed across demographics and geography. Fewer dermatologists practice in Black-majority communities, correlating directly with higher out-of-pocket spending on over-the-counter products among Black patients. When specialist care isn’t available locally, patients either travel significant distances for appointments—a burden many cannot afford—or resign themselves to self-treatment with drugstore remedies. This geographic inequality means that acne severity and treatment quality depend partly on zip code rather than on clinical need alone.
The consequence is measurable. Black patients with acne report higher out-of-pocket costs and lower satisfaction with acne management compared to patients in areas with adequate dermatological coverage. A White teenager in an affluent suburb might receive prescription treatment and dermatology follow-up, while a Black teenager with the same clinical presentation in an underserved area spends her own money on ineffective over-the-counter treatments. These disparities reflect broader healthcare inequities and contribute directly to the undertreatment of acne in vulnerable populations.
Is Acne Becoming More Common Among Adults?
Adult acne is not merely prevalent—it is rapidly increasing. Between 1990 and 2021, global adult acne incidence increased by 66.6%, reaching 20.3 million cases. This trend represents more than just awareness or diagnostic improvements; actual prevalence of acne in adult populations is rising significantly. Among women, the problem is even more pronounced: adult women experience acne at rates 25% higher than adult men globally.
In the United States specifically, 50% of women in their 20s experience acne, declining to 33% in their 30s and 25% in their 40s—still substantial percentages compared to previous generations. Projections suggest this trend will continue through 2030, meaning acne will become an even more significant public health concern. Yet healthcare systems and pharmaceutical coverage have not scaled accordingly. Insurance companies, pharmaceutical manufacturers, and dermatology practices have not proportionally increased access or resources despite this rising disease burden. The result is that the problem of undertreatment is not stable; it is worsening as more people develop acne in an environment with inadequate treatment infrastructure.
Why Does Insurance Denial of Newer Treatments Perpetuate Undertreatment?
Insurance plans systematically deny coverage for newer acne treatments in favor of older, cheaper alternatives. While generic tretinoin costs insurers less than newer retinoids, it may be less tolerable or effective for individual patients. Insurance companies operate under cost-containment mandates that prioritize affordability over optimal clinical outcomes. A patient who experiences significant irritation from tretinoin might benefit greatly from a newer retinoid, but their insurance company will require them to fail tretinoin first—a process called “step therapy”—before approving the preferred medication.
This creates a treatment delay that can have lasting consequences. During the months required to complete step therapy and wait for insurance approval, acne may worsen, leading to permanent scarring. The patient, frustrated by the bureaucratic process and the ineffective first medication, may abandon dermatological care entirely. Insurance coverage policies thus represent a hidden but significant barrier to acne treatment, one that particularly harms patients whose skin tolerability issues or clinical presentations require newer therapeutic options.
How Do Regional Variations Affect Global Acne Treatment?
Acne treatment challenges are not uniform worldwide. Western Europe has the highest age-standardized prevalence and incidence rates of acne globally, yet it also has relatively good access to dermatological care compared to other regions. In contrast, North Africa and the Middle East experienced the largest increase in acne rates between 1990 and 2021.
In these regions, the combination of rising prevalence and limited dermatological infrastructure creates an especially acute undertreatment crisis. Patients in rapidly developing areas may lack access to prescription treatments altogether, relying instead on traditional remedies or unregulated over-the-counter products of uncertain efficacy. This global variation in prevalence and access suggests that acne undertreatment is not a problem that will self-correct. Regions experiencing the highest increases in acne incidence often have the fewest resources to address it, creating worsening disparities in treatment outcomes around the world.
What Does the Future Hold for Acne Treatment Access?
The undertreatment of acne persists because the problem remains partially invisible to healthcare systems and policymakers. Acne is not immediately life-threatening, which can lead it to be deprioritized compared to serious illnesses. However, its massive prevalence, the rising incidence especially among adults, and its significant impact on quality of life and self-esteem argue for treating acne as a serious public health concern worthy of systemic intervention.
Addressing undertreatment will require action at multiple levels: insurance reform to expand coverage for effective treatments, dermatology workforce expansion in underserved communities, patient education to improve self-recognition and healthcare-seeking behavior, and primary care training to better identify and manage acne. The persistence of acne undertreatment despite the condition’s ubiquity suggests that prevalence alone does not guarantee access or quality of care. Without deliberate intervention, the trends toward rising incidence and persistent treatment barriers will likely continue, leaving millions more people struggling with a treatable skin condition.
Conclusion
Acne is simultaneously the most common skin condition and one of the most undertreated. The disconnect between prevalence and treatment access stems from multiple reinforcing factors: cost barriers that make prescription treatment unaffordable, insurance denials that reserve effective medications for patients who fail cheaper alternatives first, healthcare access disparities that leave underserved communities without specialist care, and patients’ own underestimation of acne severity. These barriers are not random; they reflect systemic inequities in healthcare access and pharmaceutical coverage.
The rising trend of acne incidence—particularly among adults and in certain global regions—means this undertreatment crisis will worsen without intervention. If you are struggling with acne, recognize that your condition is treatable and that professional care is worth pursuing, even if access is challenging. Work with your primary care provider, explore whether your insurance has any coverage for dermatological care, and if cost is a barrier, ask your dermatologist about generic alternatives or patient assistance programs. For healthcare providers and policymakers, the challenge is clear: acne’s commonality should not obscure the real suffering it causes or the genuine need for better access to evidence-based treatment.
